BibTex RIS Kaynak Göster

Serum Lipids in Patients with White Coat Hypertension

Yıl 2012, Cilt: 19 Sayı: 4, 208 - 212, 01.08.2012

Öz

Aim: Serum lipid levels were investigated in white coat hypertension in comparison with essential hypertension and normotension. Material and Methods: We selected three groups of patients, 40 essential hypertensives, 40 white coat hypertensives, and 40 normotensives. Blood samples were taken in the morning from peripheral veins after 12 hours fasting period. Plasma concentrations of total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and glucose were determined by the enzymatic dry chemistry method using a Behring apparatus. Low-density lipoprotein (LDL) cholesterol values were computed according to the Friedewald formula. Results: Mean office blood pressure values were significantly higher in hypertensive patients and white coat hypertensive patients than those of control subjects (p<0.001). Mean ambulatory blood pressure monitoring values were significantly higher in hypertensive patients than those of white coat hypertensives patients and control subjects but they were similar in white coat hypertensives patients and control subjects (p<0.001 and p>0.05, respectively). Total cholesterol and triglycerides levels were slightly higher in patients with hypertensive patients than white coat hypertensives and control groups, but this different was not significant statistically (p=0.07). Plasma HDL cholesterol, LDL cholesterol and glucose levels were not significantly different in each group (p>0.05). Conclusion: Our data demonstrate that white coat hypertensive patients present similar lipid profile to normotensive people, so in our opinion, the white coat hypertension is a benign condition. Key words: White Coat; Hypertension; Serum Lipids.

Kaynakça

  • Björklund K, Lind L, Vessby B, Andrén B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: A population-based study of elderly men. Circulation 2002;106:63-8.
  • Hoegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994;24:101-5.
  • Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998;31:57-63.
  • Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F, et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995;26:801-7.
  • Cavallini MC, Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 1995;26:413-9.
  • Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic independent of obesity. Metabolism 1990;39:167-74.
  • Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. “White coat” versus “sustained” borderline hypertension in Tecumseh, Michigan. Hypertension 1990;16:617-23.
  • Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10- year follow-up study. Circulation 1998;98:1892-7.
  • Gosse P, Promax H, Durandet P, Clementy J. „White coat‟ hypertension: No harm for the heart. Hypertension 1993;22:766-70.
  • Pall D, Juhasz M, Lengyel S, Molnar C, Paragh G, Fulesdi B. Assessment of target-organ damage in adolescent white-coat and sustained hypertensives. J Hypertens 2010;28:2139-44.
  • Ihm SH, Youn HJ, Park CS, Kim HY, Chang K, Seung KB, et al. Target organ status in white-coat hypertensives: Usefulness of serum procollagen type I propeptide in the respect of left ventricular diastolic dysfunction. Circ J 2009;73:100-5.
  • Gustavsen PH, Hİegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J Hum Hypertens 2003;17:811-7.
  • Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008;49:449-57.
  • Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011;8:686-93.
  • Yoon HJ, Ahn Y, Park JB, Park CG, Youn HJ, Choi DJ et al. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension? Clin Exp Hypertens 2010;32:480-5.

Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri

Yıl 2012, Cilt: 19 Sayı: 4, 208 - 212, 01.08.2012

Öz

Amaç: Bu çalışmanın amacı Süleyman Demirel Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı polikliniklerinden H1N1 ön tanısı ile yatırılan hastaların klinik ve epidemiyolojik özelliklerinin değerlendirilmesidir. Gereç ve Yöntemler: Süleyman Demirel Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları polikliniklerinden H1N1v ön tanısı ile yatırılan 64 hasta retrospektif olarak değerlendirilmiş, hastaların demografik özellikleri, klinik bulguları, laboratuar ve radyolojik bulguları incelenmiştir. Bulgular: Pandemik influenza ön tanısı ile yatırılarak izlenen hastaların yaş ortalaması 32,4 ay (1–188 ay) ve %34'ü (n=22) kız hastalardı. Hastaların %14'ü (n=9) kesin vaka olarak doğrulandı. En sık şikayet öksürük (%85,9), ateş (%68,8) ve halsizlik (%57,8) olarak saptandı. H1N1v pozitif hastaların %55,5'inde (n=5) nörolojik, metabolik, konjenital kalp hastalığı gibi altta yatan bir hastalık tespit edildi. Sonuç: Pandemik influenzanın klinik bulguları mevsimsel influenza ile oldukça benzerdir. Altta yatan bir hastalığın olması durumunda mortalite ve morbiditesi artmaktadır. Anahtar kelimeler: Pandemik İnfluenza; H1N1v; Aşı.

Kaynakça

  • Björklund K, Lind L, Vessby B, Andrén B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: A population-based study of elderly men. Circulation 2002;106:63-8.
  • Hoegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994;24:101-5.
  • Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998;31:57-63.
  • Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F, et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995;26:801-7.
  • Cavallini MC, Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 1995;26:413-9.
  • Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic independent of obesity. Metabolism 1990;39:167-74.
  • Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. “White coat” versus “sustained” borderline hypertension in Tecumseh, Michigan. Hypertension 1990;16:617-23.
  • Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10- year follow-up study. Circulation 1998;98:1892-7.
  • Gosse P, Promax H, Durandet P, Clementy J. „White coat‟ hypertension: No harm for the heart. Hypertension 1993;22:766-70.
  • Pall D, Juhasz M, Lengyel S, Molnar C, Paragh G, Fulesdi B. Assessment of target-organ damage in adolescent white-coat and sustained hypertensives. J Hypertens 2010;28:2139-44.
  • Ihm SH, Youn HJ, Park CS, Kim HY, Chang K, Seung KB, et al. Target organ status in white-coat hypertensives: Usefulness of serum procollagen type I propeptide in the respect of left ventricular diastolic dysfunction. Circ J 2009;73:100-5.
  • Gustavsen PH, Hİegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J Hum Hypertens 2003;17:811-7.
  • Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008;49:449-57.
  • Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011;8:686-93.
  • Yoon HJ, Ahn Y, Park JB, Park CG, Youn HJ, Choi DJ et al. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension? Clin Exp Hypertens 2010;32:480-5.
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Aytekin Güven Bu kişi benim

Yayımlanma Tarihi 1 Ağustos 2012
Yayımlandığı Sayı Yıl 2012 Cilt: 19 Sayı: 4

Kaynak Göster

APA Güven, A. (2012). Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri. Journal of Turgut Ozal Medical Center, 19(4), 208-212.
AMA Güven A. Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri. J Turgut Ozal Med Cent. Ağustos 2012;19(4):208-212.
Chicago Güven, Aytekin. “Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri”. Journal of Turgut Ozal Medical Center 19, sy. 4 (Ağustos 2012): 208-12.
EndNote Güven A (01 Ağustos 2012) Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri. Journal of Turgut Ozal Medical Center 19 4 208–212.
IEEE A. Güven, “Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri”, J Turgut Ozal Med Cent, c. 19, sy. 4, ss. 208–212, 2012.
ISNAD Güven, Aytekin. “Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri”. Journal of Turgut Ozal Medical Center 19/4 (Ağustos 2012), 208-212.
JAMA Güven A. Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri. J Turgut Ozal Med Cent. 2012;19:208–212.
MLA Güven, Aytekin. “Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri”. Journal of Turgut Ozal Medical Center, c. 19, sy. 4, 2012, ss. 208-12.
Vancouver Güven A. Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri. J Turgut Ozal Med Cent. 2012;19(4):208-12.